Kyowa Hakko Kirin

xhl_corporate_logo_vertical_k_rgbKyowa Hakko Kirin (KHK) is a biopharmaceutical company focusing on its core business area of oncology, nephrology, and immunology/allergy. KHK discovered KRN23, an investigational fully human monoclonal antibody administered via subcutaneous injection designed to bind and thereby reduce the excess biological activity of FGF23. KHK formed a collaboration with Ultragenyx to jointly develop KRN23 for the treatment of X-Linked Hypophosphatemia (XLH), a rare genetic metabolic bone disease, and Tumor- Induced Osteomalacia (TIO). Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.